Rapid Micro Biosystems Inc - Class A risk profile
41 Elevated one input has moved against it
Measured 21 October 2026 from RPID's filed statements. Recomputed nightly.
41 (Elevated), driven by Cash conversion at 100, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 83 | Acute | Volatile | One-year price volatility — 81.6% |
| Operating pressure | 2 | Contained | Stable | Input-cost exposure — 0.03 |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.03x |
| Leverage and coverage | 38 | Normal | Stable | Interest cover — -40.50x |
| Competitive position | 60 | Stretched | Stable | Operating-margin gap against peers — -95.8 percentage points |
| Concentration | 30 | Normal | Stable | Geographic concentration — 2,275 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Rapid Micro Biosystems Inc - Class A